Linpharma, a global leader in high quality supplement distribution, has announced the launch of a unique and highly effective cold sore treatment, Lyranda, in the United States. Lyranda is a convenient and pleasant-tasting lozenge, eliminating the need for messy creams to apply topically, no need to touch the cold sore, and cutting the healing time compared to other popular remedies.
Already the best-selling cold sore remedy in Germany, where the patented supplement is manufactured, Lyranda, is now available without a prescription in the U.S.
Lyranda's effectiveness comes from its multi-faceted approach to treating cold sores:
Cold sores are caused by the herpes virus.
Lyranda acts as an antiviral, stopping viral reproduction.
Its ingredients bolster the immune system.
Lyranda promotes faster wound healing.
In clinical studies, 61.7% of those with cold sores taking Lyandra were healed and symptom free in 5 days compared to only 10.9% taking other therapies. Lyranda not only reduces the symptoms of cold sores but also reduces their incidence.
Lyranda is a business success story as well as a medical one. Lyranda is driving category growth in Germany since its introduction several years ago, with a 7.5% increase in sales, despite a 4% decline for major competitors like Zovirax Cream during the same period. Total cold sore remedies as a category will reach $1.32 billion in the U.S by 2026.
Lyranda is manufactured by German pharmaceutical company Weber & Weber GmbH and sold in the U.S. by Linpharma Inc. "We are thrilled to finally bring Lyranda to the U.S. market", says Volker Gallichio, Chief Business & Market Development Officer of Linpharma. "After its success in Germany, we are confident that Lyranda will revolutionize the treatment of cold sores in the United States as well."
